#areglp1medicationssafelongterm

A 40% dropout rate shows semaglutide’s hidden price tag goes beyond the drug itself—physicians must weigh cost, side effects and long‑term safety. Click to see

A new study shows semaglutide can cut weight by nearly 30% compared with placebo, yet an 8% rebound risk looms. Discover why the safety profile matters before y

Less than 1% of patients on semaglutide or tirzepatide develop dependence—far lower than opioids. Find out why GLP‑1 drugs stay safe and how that shapes obesity